A Patient with Non-alcoholic Steatohepatitis Complicated by Multiple Myeloma

被引:1
|
作者
Akashi, Momoko [1 ]
Tajiri, Kazuto [1 ]
Wada, Akinori [2 ]
Tsuneyama, Koichi [3 ]
Kawai, Kengo [1 ]
Yasumura, Satoshi [1 ]
Minemura, Masami [1 ]
Takahara, Terumi [1 ]
Sugiyama, Toshiro [1 ,2 ]
机构
[1] Toyama Univ Hosp, Dept Gastroenterol, Toyama, Japan
[2] Toyama Univ Hosp, Dept Hematol, Toyama, Japan
[3] Grad Sch Biomed Sci, Dept Pathol & Lab Med, Toyama, Japan
关键词
non-alcoholic steatohepatitis; multiple myeloma; osteopontin; hedgehog pathway; FATTY LIVER-DISEASE; HEDGEHOG PATHWAY ACTIVATION; FIBROSIS PROGRESSION; STAGING SYSTEM; OSTEOPONTIN; CELLS;
D O I
10.2169/internalmedicine.0092-17
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A 68-year-old woman with liver dysfunction was diagnosed with nonalcoholic steatohepatitis (NASH) stage 1. Three years later, she showed massive ascites and jaundice. A trans-jugular liver biopsy confirmed advanced cirrhosis, suggesting that her liver fibrosis had progressed rapidly. At the same time, she was diagnosed with multiple myeloma (MM). In this case, the plasma levels of osteopontin (OPN), a proinflammatory cytokine that promotes liver fibrosis progression through the hedgehog pathway and is increased in patients with MM, were increased. This increased OPN expression was accompanied by the upregulation of the hedgehog pathway in this patient, suggesting that the MM-associated increase in OPN had promoted the progression of liver fibrosis through the hedgehog pathway. The progression of liver fibrosis should be monitored in patients with NASH if other diseases, such as MM, are present.
引用
收藏
页码:2013 / 2018
页数:6
相关论文
共 50 条
  • [21] Saroglitazar for non-alcoholic steatohepatitis
    Baker, Holly
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2021, 6 (09): : 698 - 698
  • [22] Mechanisms of non-alcoholic steatohepatitis
    McClain, CJ
    Mokshagundam, PL
    Barve, SS
    Song, ZY
    Hill, DB
    Chen, T
    Deaciuc, I
    ALCOHOL, 2004, 34 (01) : 67 - 79
  • [23] Metformin in non-alcoholic steatohepatitis
    Marchesini, G
    Brizi, M
    Bianchi, G
    Tomassetti, S
    Zoli, M
    Melchionda, N
    LANCET, 2001, 358 (9285): : 893 - 894
  • [24] Selonsertib for non-alcoholic steatohepatitis
    Baker, Holly
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2017, 2 (12): : 852 - 852
  • [25] Treatment of non-alcoholic steatohepatitis
    Angulo, P
    Lindor, KD
    BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, 2002, 16 (05) : 797 - 810
  • [26] Fructose and Non-Alcoholic Steatohepatitis
    Roeb, Elke
    Weiskirchen, Ralf
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [27] Diagnosis of non-alcoholic steatohepatitis
    James, OFW
    STEATOHEPATITIS (NASH AND ASH), 2001, 121 : 34 - 39
  • [28] News on non-alcoholic steatohepatitis
    Roeb, E.
    Nitschmann, S.
    INTERNIST, 2022, 63 (02): : 238 - 242
  • [29] Non-alcoholic steatohepatitis (NASH)
    Michael F. Sorrell
    Sandeep Mukherjee
    Current Treatment Options in Gastroenterology, 1999, 2 (6) : 447 - 450
  • [30] Metformin in non-alcoholic steatohepatitis
    Urso, R
    Visco-Comandini, U
    LANCET, 2002, 359 (9303): : 355 - 356